Medical interventions for the prevention of platinum-induced hearing loss in children with cancer

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 9, 2016, Pages

  van As, Jorrit W ^a   van den Berg, Henk ^a   van Dalen, Elvira C ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CARBOPLATIN; CISPLATIN; PLACEBO; PLATINUM;

CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHILDHOOD CANCER; HEARING IMPAIRMENT; HEPATOBLASTOMA; HUMAN; NEPHROTOXICITY; OSTEOSARCOMA; OTOTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL; SYSTEMATIC REVIEW; TINNITUS; TREATMENT RESPONSE; VOMITING;

EID: 84989229062     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009219.pub4     Document Type: Review

References (58)

1. Gallegos-Castorena S, Martínez-Avalos A, Mohar-Betancourt A, Guerrero-Avendaño G, Zapata-Tarrés M, Medina-Sansón A. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. Pediatric Hematology and Oncology 2007;24(6):403-8.
2. Katzenstein HM, Chang KW, Krailo M, Chen Z, Finegold MJ, Rowland J, et al. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group. Cancer 2009;115(24):5828-35.
3. Petrilli AS, Oliveira DT, Ginani VC, Kechichian R, Dishtchekenian A, De Medeiros Roque Filho W, et al. Use of amifostine in the therapy of osteosarcoma in children and adolescents. Journal of Pediatric Hematology/Oncology 2002;24(3):188-91.
4. Petrilli AS, de Camargo B, Filho VO, Bruniera P, Brunetto AL, Jesus-Garcia R, et al. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. Journal of Clinical Oncology 2006;24(7):1161-8.
5. Doolittle ND, Muldoon LL, Brummett RE, Tyson RM, Lacy C, Bubalo JS, et al. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clinical Cancer Research 2001;7(3):493-500.
6. Elsendoorn TJ, Weijl NI, Mithoe S, Zwinderman AH, Van Dam F, De Zwart FA, et al. Chemotherapy-induced chromosomal damage in peripheral blood lymphocytes of cancer patients supplemented with antioxidants or placebo. Mutation Research 2001;498(1-2):145-58.
7. Fouladi M, Chintagumpala M, Ashley D, Kellie S, Gururangan S, Hassall T, et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. Journal of Clinical Oncology 2008;26(22):3749-55.
8. Geoerger B, Vassal G, Doz F, O'Quigley J, Wartelle M, Watson AJ, et al. Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies. British Journal of Cancer 2005;93(5):529-37.
9. Grau JJ, Estape J, Cuchi MA, Firvida JL, Blanch JL, Ascaso C. Calcium supplementation and ototoxicity in patients receiving cisplatin. British Journal of Clinical Pharmacology 1996;42(2):233-5.
10. Gurney JG, Bass JK, Onar-Thomas A, Huang J, Chintagumpala M, Bouffet E, et al. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. Neuro-Oncology 2014;16(6):848-55.
11. Kingston JE, Abramovich S, Billings RJ. Assessment of the effect of chemotherapy and radiotherapy on the auditory function of children with cancer. Clinical Otolaryngology and Allied Sciences 1986;11:403-9.
12. Knight K. Hearing loss in pediatric cancer survivors treated with cisplatin. Oncology (Williston Park) 2008;22(4 Suppl Nurse Edition):35-7.
13. Ladenstein R, Valteau CD, Brock P, Yaniv I, Castel V, Laureys G, et al. Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. Journal of Clinical Oncology 2010;28:3516-24.
14. Mahoney DH, Weaver T, Steuber CP, Starling KA. Cis-platinum (CDDP) ototoxicity in pediatric patients. Proceedings of the American Society of Clinical Oncology 1982:26.
15. Mahoney DH Jr, Weaver T, Steuber CP, Starling KA. Ototoxicity with cisplatin therapy. Journal of Pediatrics 1983;103(6):1006-7.
16. Marina N, Chang KW, Malogolowkin M, London WB, Frazier AL, Womer RB, et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Cancer 2005;104(4):841-7.
17. McHaney VA, Thibadoux G, Hayes FA, Green AA. Hearing loss in children receiving cisplatin chemotherapy. Journal of Pediatrics 1983;102(2):314-7.
18. Meyer AK, Young NM. Auditory late effects of chemotherapy. Cancer Treatment and Research 2009;150:195-213.
19. Piel IJ, Meyer D, Perlia CP, Wolfe VI. Effects of cis-diamminedichloroplatinum (NSC-119875) on hearing function in man. Cancer Chemotherapy Reports 1974;58(6):871-5.
20. Skinner R. Preventing platinum-induced ototoxicity in children - is there a potential role for sodium thiosulfate?. Pediatric Blood and Cancer 2006;47(2):120-2.
21. Spunt SL, Freeman BB III, Billups CA, McPherson V, Khan RB, Pratt CB, et al. Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors. Journal of Clinical Oncology 2007;25(16):2274-80.
22. Sullivan MJ. Hepatoblastoma, cisplatin, and ototoxicity: good news on deaf ears. Cancer 2009;115(24):5623-6.
23. Weijl NI, Elsendoorn TJ, Lentjes EG, Hopman GD, Wipkink-Bakker A, Zwinderman AH, et al. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. European Journal of Cancer 2004;40(11):1713-23.
24. Freyer DR. The effects of sodium thiosulfate (STS) on cisplatin-induced hearing loss: a report from the Children's Oncology Group. Journal of Clinical Oncology 2014;5s:abstract 10017.
25. Maibach R, Childs M, Rajput K, Neuwelt EA, Roebuck D, Sullivan MJ, et al. SIOPEL 6: a multicenter open-label randomized phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard-risk hepatoblastoma (SR-HB). Journal of Clinical Oncology 2014;5s:abstract TPS10094.
26. Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. Journal of Pediatric Hematology/Oncology 2004;26(10):649-55.
27. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J. Cisplatin ototoxicity in children: a practical grading system. Medical and Pediatric Oncology 1991;19(4):295-300.
28. Jenney MEM. Late effects of cancer treatment and current protective measures. In: Voûte PA, Barett A, Stevens MCG, Caron HN editor(s). Cancer in Children. Fifth. Oxford University Press, 2005:123-37.
29. Dean JB, Hayashi SS, Albert CM, King AA, Karzon R, Hayashi RJ. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. Journal of Pediatric Hematology/Oncology 2008;30(2):130-4.
30. Eloxatin summary of product characteristics. www.sanofi-aventis.co.uk/products/Eloxatin_SPC.pdf (assessed 2 March 2010).
31. Freyer DR, Sung L, Reaman GH. Prevention of hearing loss in children receiving cisplatin chemotherapy. Journal of Clinical Oncology 2009;27(2):317-8.
32. Gallagher KL, Jones JK. Furosemide-induced ototoxicity. Annals of Internal Medicine 1979;91(1):744-5.
33. Gietema JA, Meinardi MT, Messerschmidt J, Gelevert T, Alt F, Uges DR, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000;355(9209):1075-6.
34. McMaster University. GRADEprofiler 3.6.1. McMaster University, 2011.
35. Gregg RB, Wiorek LS, Arvedson JC. Pediatric audiology: a review. Pediatrics in Review 2004;25(7):224-33.
36. Grewal S, Merchant T, Reymond R, McInerney M, Hodge C, Shearer P. Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group. Pediatrics 2010;125(4):e938-50.
37. Gurney JG, Tersak JM, Ness KK, Landier W, Matthay KK, Schmidt ML, Children's Oncology Group. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group. Pediatrics 2007;120(5):e1229-36.
38. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
39. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. Journal of Clinical Oncology 2005;23(34):8588-96.
40. Lachin JM. Statistical considerations in the intent-to-treat principle. Controlled Clinical Trials 2000;21:167-89.
41. Leclercq E, Leeflang MM, van Dalen EC, Kremer LC. Validation of search filters for identifying pediatric studies in PubMed. Journal of Pediatrics 2013;162(3):629-34.
42. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. European Journal of Cancer 2004;40(16):2445-51.
43. Kremer LCM, van Dalen EC, Moher D, Caron HN. Cochrane Childhood Cancer Group. About the Cochrane Collaboration (Cochrane Review Groups (CRGs) 2010, Issue 12:Art. No.: CHILDCA.
44. National Cancer Institute Common Toxicity Criteria version 2. ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
45. Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersall MH. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treatment Reports 1982;66(1):19-23.
46. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
47. Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nature Genetics 2009;41(12):1345-9.
48. Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hearing Research 2007;226(1-2):157-67.
49. Rybak LP, Mukherjea D, Jajoo S, Ramkumar V. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku Journal of Experimental Medicine 2009;219(3):177-86.
50. Schell MJ, McHaney VA, Green AA, Kun LE, Hayes FA, Horowitz M, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. Journal of Clinical Oncology 1989;7(6):754-60.
51. Skinner R. Best practice in assessing ototoxicity in children with cancer. European Journal of Cancer 2004;40(16):2352-4.
52. Van As JW, van den Berg H, van Dalen EC. Different infusion durations for preventing platinum-induced hearing loss in children with cancer. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD010885.pub2]
53. Van As JW, van den Berg H, van Dalen EC. Platinum-induced hearing loss after treatment for childhood cancer. Cochrane Database of Systematic Reviews 2016, Issue 8. [DOI: 10.1002/14651858.CD010181.pub2]
54. Van As JW, van den Berg H, van Dalen EC. Different infusion durations for preventing platinum-induced hearing loss in children with cancer. Cochrane Database of Systematic Reviews 2016, Issue 8. [DOI: 10.1002/14651858.CD010885.pub3]
55. Veal GJ, Dias C, Price L, Parry A, Errington J, Hale J, et al. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy. Clinical Cancer Research 2001;7(8):2205-12.
56. Van As JW, van den Berg H, van Dalen EC. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database of Systematic Reviews 2011, Issue 7. [DOI: 10.1002/14651858.CD009219]
57. Van As JW, van den Berg H, van Dalen EC. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009219.pub2]
58. Van As JW, van den Berg H, van Dalen EC. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD009219.pub3]